Journal of Cancer Education

, 26:420

The International Core Literature Consensus (ICLC): an Alternative Curriculum for Oncologists

  • Shilpen Patel
  • Reshma Jagsi
  • Natalie Cook
  • Luke Hughes-Davies
  • Christine Parkinson
Article

Abstract

Oncologists must familiarize themselves with a complex evidence base. Several curricula have been devised, but it is not clear how these are used. We chose breast cancer, since this has a large literature base. Of the 285 radiation and medical oncology trainees in the USA and UK responding to our survey, over 90% reported knowledge of the literature was essential. Just over half of respondents had actually read the ASCO or ESMO curricula, with only 23% reporting that the curricula were important in their learning. Our survey revealed dissatisfaction with current curricula and a demand for more pragmatic literature guidance. We designed an alternative curriculum by using a 21-member peer review group to validate a list of key papers in breast oncology. Oncologists in training need guidance to direct their study. A curriculum based on an International Core Literature Consensus might match the needs of trainees more closely.

Keywords

Breast cancer Evidence base Curriculum 

References

  1. 1.
    DeVita VT, Hellman S, Rosenberg SA (2004) Cancer: principles and practice of oncology (7th edn). Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    Muss HB, Roenn JV, Damon LE et al (2005) ACCO: ASCO core curriculum outline. J Clin Oncol 23:2049–2077PubMedCrossRefGoogle Scholar
  3. 3.
    Hansen HH, Bajorin DF, Muss HB et al (2004) Recommendations for a global core curriculum in medical oncology. Ann Oncol 16:1603–1612Google Scholar
  4. 4.
    ASCO (2003) RCP: curriculum for medical oncology www.jchmt.org.uk/medonc/curr_medoncology.pdf. Accessed 2006
  5. 5.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  7. 7.
    Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMedGoogle Scholar
  8. 8.
    Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949–955PubMedCrossRefGoogle Scholar
  9. 9.
    Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102PubMedGoogle Scholar
  10. 10.
    Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRefGoogle Scholar
  11. 11.
    Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRefGoogle Scholar
  12. 12.
    Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437PubMedCrossRefGoogle Scholar
  13. 13.
    Holland R, Veling SH, Mravunac M et al (1985) Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56:979–990PubMedCrossRefGoogle Scholar
  14. 14.
    National Institutes of Health Consensus Development Panel (2001) The National Institutes of Health Consensus Development Conference: Adjuvant therapy for breast cancer. Bethesda, Maryland, USA, November 1–3, 2000. Proceedings. J Natl Cancer Inst Monogr, 1–152Google Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Shilpen Patel
    • 1
  • Reshma Jagsi
    • 2
  • Natalie Cook
    • 3
  • Luke Hughes-Davies
    • 3
  • Christine Parkinson
    • 3
  1. 1.University of WashingtonSeattleUSA
  2. 2.University of MichiganAnn ArborUSA
  3. 3.Addenbrooke’s HospitalCambridgeUK

Personalised recommendations